π£ VC round data is live. Check it out!
- Public Comps
- Organigram Global
Organigram Global Valuation Multiples
Discover revenue and EBITDA valuation multiples for Organigram Global and similar public comparables like Cannara Biotech, Ispire Technology, Ascend Wellness Holdings, Jushi Holdings and more.
Organigram Global Overview
About Organigram Global
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag Oβ Buds, SHRED, SHREDβems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Founded
2010
HQ

Employees
1.2K
Website
Sectors
Financials (LTM)
EV
$155M
Valuation Multiples
Start free trialOrganigram Global Financials
Organigram Global reported last 12-month revenue of $227M and EBITDA of $17M.
In the same LTM period, Organigram Global generated $82M in gross profit, $17M in EBITDA, and $3M in net income.
Revenue (LTM)
Organigram Global P&L
In the most recent fiscal year, Organigram Global reported revenue of $189M and EBITDA of $14M.
Organigram Global is unprofitable as of last fiscal year, with gross margin of 35%, EBITDA margin of 7%, and net margin of (10%).
Financial data powered by Morningstar, Inc.
Organigram Global Stock Performance
Organigram Global has current market cap of $153M, and enterprise value of $155M.
Market Cap Evolution
Organigram Global's stock price is $1.08.
Organigram Global share price decreased by 22.3% in the last 30 days, and by 18.2% in the last year.
Organigram Global has an EPS (earnings per share) of $-0.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $155M | $153M | 2.9% | -22.3% | -23.9% | -18.2% | $-0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOrganigram Global Valuation Multiples
Organigram Global trades at 0.7x EV/Revenue multiple, and 9.2x EV/EBITDA.
EV / Revenue (LTM)
Organigram Global Financial Valuation Multiples
As of May 21, 2026, Organigram Global has market cap of $153M and EV of $155M.
Organigram Global has a P/E ratio of 56.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Organigram Global Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Organigram Global Margins & Growth Rates
Organigram Global grew revenue by 32% and EBITDA by 38% in the last fiscal year.
In the most recent fiscal year, Organigram Global reported gross margin of 35%, EBITDA margin of 7%, and net margin of (10%).
Organigram Global Margins
Organigram Global Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Organigram Global Operational KPIs
Organigram Global's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Organigram Global's Rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Organigram Global's Rule of X is 86% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Organigram Global Competitors
Organigram Global competitors include Cannara Biotech, Ispire Technology, Ascend Wellness Holdings, Jushi Holdings, Aurora Cannabis, TerrAscend, High Tide, Grown Rogue International, Planet 13 and WM Tech.
Most Organigram Global public comparables operate across Cannabis.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.7x | 1.6x | 6.5x | 6.0x | |||
| 0.8x | 1.1x | (3.3x) | (35.2x) | |||
| β | 1.3x | β | 5.7x | |||
| β | 1.4x | β | 7.3x | |||
| 0.8x | 0.8x | 5.4x | 4.9x | |||
| β | 1.6x | β | 6.2x | |||
| 0.7x | 0.6x | 10.4x | 8.6x | |||
| β | β | β | β | |||
This data is available for Pro users. Sign up to see all Organigram Global competitors and their valuation data. Start Free Trial | ||||||
Organigram Global M&A Activity
Organigram Global has acquired 5 companies to date.
Last acquisition by Organigram Global was on February 18th 2026. Organigram Global acquired Sanity Group for $295M (EV/Revenue multiple of ).
Latest Acquisitions by Organigram Global
| Description | Sanity Group is a Berlin-headquartered producer of cannabinoid-infused wellness products across Europe, emphasizing non-psychoactive CBD formulations for health and relaxation. It manufactures oils, cosmetics, beverages and supplements under its own labels, distributed in Germany, Czech Republic, Poland and Austria via pharmacies, health stores and online platforms. Founded in 2018, the company invests in clinical research partnerships with universities like Charles University, achieving B Corp certification and expanding production capacity to 500,000 units annually by 2023. | Motif Labs is an Aylmer-headquartered cannabis processor in Ontario licensed under Health Canada for extraction and formulation of oils, edibles, and vapes. It operates a 50,000-square-foot facility using CO2 supercritical methods to produce full-spectrum distillates for brands like Tokyo Smoke. Services include white-label packaging and R&D for terpene profiles targeting recreational markets. | Laurentian Organic produces certified organic cannabis flowers hand-crafted and cured alongside premium hash products for recreational and medical consumers. Quebec-based in the Laurentides region, the company prioritizes sustainable cultivation methods and quality control in its licensed production facility. Products distribute through provincial cannabis retail networks across Canada. | Edibles & Infusions is a cannabis edibles manufacturer specializing in soft chews and gummies sold through dispensaries in Canada. Operating under Agraflora Organics International, the British Columbia-based processor produces THC and CBD-infused products in flavors like watermelon and berry. Facilities in Delta meet Health Canada standards for GMP compliance. Launched in 2019, the brand distributes over 20 SKUs to provinces including Ontario and Alberta. Edibles & Infusions emphasizes precise dosing with 10mg THC per piece and natural fruit purees. | |
| HQ Country | |||||
| HQ City | Berlin | London | Quebec City | Winnipeg | |
| Deal Date | 18 Feb 2026 | 6 Dec 2024 | 21 Dec 2021 | 6 Apr 2021 | |
| Valuation | $295M | $90M | $27M | $22M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Organigram Global acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Organigram Global Investment Activity
Organigram Global has invested in 5 companies to date.
Latest investment by Organigram Global was on December 31st 2025. Organigram Global invested in Phylos in their $3M Undisclosed stage round (EV/Revenue multiple of ).
Latest Investments by Organigram Global
| Description | Phylos is a Portland-headquartered crop science company specializing in hemp and cannabis breeding. Founded in 2014, it applies molecular genetics and computational biology to develop seeds and clones with uniform traits for potency, vigor, and yield. Phylos maintains the largest cannabis genomic database, enabling growers to select varieties optimized for commercial cultivation in regulated markets across North America. | Phylos is a Portland-headquartered crop science company specializing in hemp and cannabis breeding. Founded in 2014, it applies molecular genetics and computational biology to develop seeds and clones with uniform traits for potency, vigor, and yield. Phylos maintains the largest cannabis genomic database, enabling growers to select varieties optimized for commercial cultivation in regulated markets across North America. | Sanity Group is a Berlin-headquartered producer of cannabinoid-infused wellness products across Europe, emphasizing non-psychoactive CBD formulations for health and relaxation. It manufactures oils, cosmetics, beverages and supplements under its own labels, distributed in Germany, Czech Republic, Poland and Austria via pharmacies, health stores and online platforms. Founded in 2018, the company invests in clinical research partnerships with universities like Charles University, achieving B Corp certification and expanding production capacity to 500,000 units annually by 2023. | Sanity Group is a Berlin-headquartered producer of cannabinoid-infused wellness products across Europe, emphasizing non-psychoactive CBD formulations for health and relaxation. It manufactures oils, cosmetics, beverages and supplements under its own labels, distributed in Germany, Czech Republic, Poland and Austria via pharmacies, health stores and online platforms. Founded in 2018, the company invests in clinical research partnerships with universities like Charles University, achieving B Corp certification and expanding production capacity to 500,000 units annually by 2023. | |
| HQ Country | |||||
| HQ City | Portland, OR | Portland, OR | Berlin | Berlin | |
| Deal Date | 31 Dec 2025 | 24 Jul 2024 | 25 Jun 2024 | 25 Jun 2024 | |
| Round | Undisclosed stage | Seed | Secondary - private | Series A | |
| Raised | $3M | $1M | $3M | $3M | |
| Investors | Organigram Global | Organigram Global | Organigram Global | Organigram Global | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Organigram Global investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Organigram Global
| When was Organigram Global founded? | Organigram Global was founded in 2010. |
| Where is Organigram Global headquartered? | Organigram Global is headquartered in Canada. |
| How many employees does Organigram Global have? | As of today, Organigram Global has over 1K employees. |
| Who is the CEO of Organigram Global? | Organigram Global's CEO is James Yamanaka. |
| Is Organigram Global publicly listed? | Yes, Organigram Global is a public company listed on Nasdaq. |
| What is the stock symbol of Organigram Global? | Organigram Global trades under OGI ticker. |
| When did Organigram Global go public? | Organigram Global went public in 2014. |
| Who are competitors of Organigram Global? | Organigram Global main competitors include Cannara Biotech, Ispire Technology, Ascend Wellness Holdings, Jushi Holdings, Aurora Cannabis, TerrAscend, High Tide, Grown Rogue International, Planet 13, WM Tech. |
| What is the current market cap of Organigram Global? | Organigram Global's current market cap is $153M. |
| What is the current revenue of Organigram Global? | Organigram Global's last 12 months revenue is $227M. |
| What is the current revenue growth of Organigram Global? | Organigram Global revenue growth (NTM/LTM) is 30%. |
| What is the current EV/Revenue multiple of Organigram Global? | Current revenue multiple of Organigram Global is 0.7x. |
| Is Organigram Global profitable? | Yes, Organigram Global is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Organigram Global? | Organigram Global's last 12 months EBITDA is $17M. |
| What is Organigram Global's EBITDA margin? | Organigram Global's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Organigram Global? | Current EBITDA multiple of Organigram Global is 9.2x. |
| What is the current FCF of Organigram Global? | Organigram Global's last 12 months FCF is ($9M). |
| What is Organigram Global's FCF margin? | Organigram Global's last 12 months FCF margin is (4%). |
| What is the current EV/FCF multiple of Organigram Global? | Current FCF multiple of Organigram Global is (17.6x). |
| How many companies Organigram Global has acquired to date? | As of May 2026, Organigram Global has acquired 5 companies. |
| What was the largest acquisition by Organigram Global? | $295M acquisition of Sanity Group on 18th February 2026 was the largest M&A Organigram Global has done to date. |
| What companies Organigram Global acquired? | Organigram Global acquired Sanity Group, Motif Labs, Laurentian Organic, Edibles & Infusions, and Trauma Healing Centers. |
| In how many companies Organigram Global has invested to date? | As of May 2026, Organigram Global has invested in 5 companies. |
| What was the last Organigram Global investment? | On 31st December 2025 Organigram Global invested in Phylos, participating in a $3M Undisclosed stage round. |
| In what companies Organigram Global invested in? | Organigram Global invested in Green Tank Technologies, Hyasynth Bio, Phylos, Sanity Group, and Open Book Extracts. |
See public comps similar to Organigram Global
Lists including Organigram Global
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.



